Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Technology, By Application, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
Description
Targeted DNA RNA Sequencing Market Summary
The global targeted DNA RNA sequencing market size was estimated at USD 7.40 billion in 2024 and is projected to reach USD 34.56 billion by 2033, expanding at a CAGR of 18.98% from 2025 to 2033. The market is growing rapidly due to the increasing use of precision medicine, the rising incidence of cancer and genetic diseases, and the demand for more cost-efficient and highly accurate sequencing methodologies that enable the deep analysis of specific genes or genomic regions.
Growing Demand for Precision Diagnostics and Targeted Therapies
With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders, the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to identify pathogenic variations at an earlier stage in the process, which facilitates diagnosis and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.
Moreover, targeted sequencing facilitates the transition to personalized, less invasive therapies, particularly in the fields of oncology and rare disease. By identifying actionable genetic mutations, clinicians can select targeted therapies that are both more effective and have lower toxicity compared to standard chemotherapy or broad-spectrum treatments. The capacity for individualized care, minimal toxicity, and improved patient outcomes continues to drive the use of targeted sequencing in the clinical, research, and pharmaceutical sectors, making it a major contributor to healthcare innovation and market expansion.
Technological Advancements and Cost Efficiency Accelerating Adoption
Advances in next-generation sequencing platforms, enrichment chemistry, and automation make targeted sequencing faster, more accurate, and significantly less costly. Innovations such as improved capture kits, high-throughput systems, and enhanced reagents are reducing processing and turnaround times, thereby supporting applications in hospitals, research laboratories, and biotech companies.
Moreover, targeted sequencing focuses on only selected gene regions, allowing for deeper coverage and increased sensitivity in detecting rarer variants, which is superior to whole-genome sequencing. Given that targeted sequencing has lower data analysis requirements, fewer storage needs, and cost-efficient workflows, it is increasingly chosen by healthcare providers in areas such as routine diagnostics, precision medicine, and large genomic programs. This value proposition, based on efficiencies, continues to drive market expansion.
Global Targeted DNA RNA Sequencing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global targeted DNA RNA sequencing market based on technology, workflow, application, type, end use, and region:
The global targeted DNA RNA sequencing market size was estimated at USD 7.40 billion in 2024 and is projected to reach USD 34.56 billion by 2033, expanding at a CAGR of 18.98% from 2025 to 2033. The market is growing rapidly due to the increasing use of precision medicine, the rising incidence of cancer and genetic diseases, and the demand for more cost-efficient and highly accurate sequencing methodologies that enable the deep analysis of specific genes or genomic regions.
Growing Demand for Precision Diagnostics and Targeted Therapies
With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders, the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to identify pathogenic variations at an earlier stage in the process, which facilitates diagnosis and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.
Moreover, targeted sequencing facilitates the transition to personalized, less invasive therapies, particularly in the fields of oncology and rare disease. By identifying actionable genetic mutations, clinicians can select targeted therapies that are both more effective and have lower toxicity compared to standard chemotherapy or broad-spectrum treatments. The capacity for individualized care, minimal toxicity, and improved patient outcomes continues to drive the use of targeted sequencing in the clinical, research, and pharmaceutical sectors, making it a major contributor to healthcare innovation and market expansion.
Technological Advancements and Cost Efficiency Accelerating Adoption
Advances in next-generation sequencing platforms, enrichment chemistry, and automation make targeted sequencing faster, more accurate, and significantly less costly. Innovations such as improved capture kits, high-throughput systems, and enhanced reagents are reducing processing and turnaround times, thereby supporting applications in hospitals, research laboratories, and biotech companies.
Moreover, targeted sequencing focuses on only selected gene regions, allowing for deeper coverage and increased sensitivity in detecting rarer variants, which is superior to whole-genome sequencing. Given that targeted sequencing has lower data analysis requirements, fewer storage needs, and cost-efficient workflows, it is increasingly chosen by healthcare providers in areas such as routine diagnostics, precision medicine, and large genomic programs. This value proposition, based on efficiencies, continues to drive market expansion.
Global Targeted DNA RNA Sequencing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global targeted DNA RNA sequencing market based on technology, workflow, application, type, end use, and region:
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- NGS
- Method
- Exome Sequencing
- Enrichment Sequencing
- Amplicon Sequencing
- Others
- Application
- Cancer Gene Sequencing
- Inherited Disease Screening
- Drug Development
- Forensic Genomics
- 16S ribosomal RNA (rRNA) sequencing
- Others
- Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Pre-sequencing
- Sequencing
- Data Analysis
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Human Biomedical Research
- Plant & Animal Sciences
- Drug Discovery
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- DNA Based Targeted Sequencing
- RNA Based Targeted Sequencing
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Technology
- 1.2.2. Workflow
- 1.2.3. Application
- 1.2.4. Type
- 1.2.5. End Use
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Targeted DNA RNA Sequencing Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.1.1. Growing Demand for Precision Diagnostics and Targeted Therapies
- 3.3.1.2. Technological Advancements and Cost Efficiency Accelerating Adoption
- 3.3.2. Market Restraints Analysis
- 3.3.2.1. High Initial Capital Investment
- 3.4. Business Environment Analysis
- 3.4.1. PESTLE Analysis
- 3.4.2. PORTER’S Five Forces Analysis
- Chapter 4. Targeted DNA RNA Sequencing Market: Technology Estimates & Trend Analysis
- 4.1. Technology Segment Dashboard
- 4.2. Targeted DNA RNA Sequencing Market: Technology Movement Analysis, USD Million, 2023 & 2033
- 4.3. NGS
- 4.3.1. NGS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Method Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.1. Exome Sequencing
- 4.3.2.1.1. Exome Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.2. Enrichment Sequencing
- 4.3.2.2.1. Enrichment Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.3. Amplicon Sequencing
- 4.3.2.3.1. Amplicon Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2.4. Others
- 4.3.2.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Application Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3.1. Cancer Gene Sequencing
- 4.3.3.1.1. Cancer Gene Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3.2. Inherited Disease Screening
- 4.3.3.2.1. Inherited Disease Screening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3.3. Drug Development
- 4.3.3.3.1. Drug Development Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3.4. Forensic Genomics
- 4.3.3.4.1. Forensic Genomics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3.5. 16S Ribosomal RNA (rRNA)
- 4.3.3.5.1. 16S Ribosomal RNA (rRNA) Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Others
- 4.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Targeted DNA RNA Sequencing Market: Workflow Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Targeted DNA RNA Sequencing Market: Workflow Movement Analysis, USD Million, 2023 & 2033
- 5.3. Pre-sequencing
- 5.3.1. Pre-sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Sequencing
- 5.4.1. Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Data Analysis
- 5.5.1. Data Analysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Targeted DNA RNA Sequencing Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Targeted DNA RNA Sequencing Market: Application Movement Analysis, USD Million, 2023 & 2033
- 6.3. Human Biomedical Research
- 6.3.1. Human Biomedical Research Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Plant & Animal Sciences
- 6.4.1. Plant & Animal Sciences Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Drug Discovery
- 6.5.1. Drug Discovery Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Targeted DNA RNA Sequencing Market: Type Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Targeted DNA RNA Sequencing Market: Type Movement Analysis, USD Million, 2023 & 2033
- 7.3. DNA Based Targeted Sequencing
- 7.3.1. DNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. RNA Based Targeted Sequencing
- 7.4.1. RNA Based Targeted Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Targeted DNA RNA Sequencing Market: End Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Targeted DNA RNA Sequencing Market: End Use Movement Analysis, USD Million, 2023 & 2033
- 8.3. Academic Research
- 8.3.1. Academic Research Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4. Hospitals & Clinics
- 8.4.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Pharma & Biotech Entities
- 8.5.1. Pharma & Biotech Entities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Others
- 8.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Targeted DNA RNA Sequencing Market: Regional Estimates & Trend Analysis
- 9.1. Targeted DNA RNA Sequencing Market Share, By Region, 2024 & 2033, USD Million
- 9.2. North America
- 9.2.1. North America Targeted DNA RNA Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key Country Dynamics
- 9.2.2.2. Competitive Scenario
- 9.2.2.3. Regulatory Framework
- 9.2.2.4. U.S. targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.2.3. Canada
- 9.2.3.1. Key Country Dynamics
- 9.2.3.2. Competitive Scenario
- 9.2.3.3. Regulatory Framework
- 9.2.3.4. Canada targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.2.4. Mexico
- 9.2.4.1. Key Country Dynamics
- 9.2.4.2. Competitive Scenario
- 9.2.4.3. Regulatory Framework
- 9.2.4.4. Mexico targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3. Europe
- 9.3.1. Europe targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Scenario
- 9.3.2.3. Regulatory Framework
- 9.3.2.4. UK targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.3. Germany
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Scenario
- 9.3.3.3. Regulatory Framework
- 9.3.3.4. Germany targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.4. France
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Scenario
- 9.3.4.3. Regulatory Framework
- 9.3.4.4. France targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.5. Italy
- 9.3.5.1. Key Country Dynamics
- 9.3.5.2. Competitive Scenario
- 9.3.5.3. Regulatory Framework
- 9.3.5.4. Italy targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.6. Spain
- 9.3.6.1. Key Country Dynamics
- 9.3.6.2. Competitive Scenario
- 9.3.6.3. Regulatory Framework
- 9.3.6.4. Spain targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.7. Denmark
- 9.3.7.1. Key Country Dynamics
- 9.3.7.2. Competitive Scenario
- 9.3.7.3. Regulatory Framework
- 9.3.7.4. Denmark targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.8. Sweden
- 9.3.8.1. Key Country Dynamics
- 9.3.8.2. Competitive Scenario
- 9.3.8.3. Regulatory Framework
- 9.3.8.4. Sweden targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.3.9. Norway
- 9.3.9.1. Key Country Dynamics
- 9.3.9.2. Competitive Scenario
- 9.3.9.3. Regulatory Framework
- 9.3.9.4. Norway targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. Japan targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.3. China
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. China targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.4. India
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. India targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.5. Australia
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Scenario
- 9.4.5.3. Regulatory Framework
- 9.4.5.4. Australia targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.6. Thailand
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Scenario
- 9.4.6.3. Regulatory Framework
- 9.4.6.4. Thailand targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.4.7. South Korea
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Scenario
- 9.4.7.3. Regulatory Framework
- 9.4.7.4. South Korea targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.5. Latin America
- 9.5.1. Latin America targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Brazil targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.5.3. Argentina
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Argentina targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.6. MEA
- 9.6.1. MEA targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. South Africa targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Saudi Arabia targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.6.4. UAE
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Competitive Scenario
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. UAE targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- 9.6.5. Kuwait
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Competitive Scenario
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Kuwait targeted DNA RNA sequencing market, 2021 - 2033 (USD Million)
- Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2024
- 10.4. Company Profiles/Listing
- 10.4.1. Illumina
- 10.4.1.1. Participant’s Overview
- 10.4.1.2. Financial Performance
- 10.4.1.3. Product Benchmarking
- 10.4.1.4. Strategic Initiatives
- 10.4.2. F. Hoffman-La Roche Ltd.
- 10.4.2.1. Participant’s Overview
- 10.4.2.2. Financial Performance
- 10.4.2.3. Product Benchmarking
- 10.4.2.4. Strategic Initiatives
- 10.4.3. QIAGEN
- 10.4.3.1. Participant’s Overview
- 10.4.3.2. Financial Performance
- 10.4.3.3. Product Benchmarking
- 10.4.3.4. Strategic Initiatives
- 10.4.4. Thermo Fisher Scientific, Inc.
- 10.4.4.1. Participant’s Overview
- 10.4.4.2. Financial Performance
- 10.4.4.3. Product Benchmarking
- 10.4.4.4. Strategic Initiatives
- 10.4.5. Bio-Rad Laboratories, Inc.
- 10.4.5.1. Participant’s Overview
- 10.4.5.2. Financial Performance
- 10.4.5.3. Product Benchmarking
- 10.4.5.4. Strategic Initiatives
- 10.4.6. Oxford Nanopore Technologies
- 10.4.6.1. Participant’s Overview
- 10.4.6.2. Financial Performance
- 10.4.6.3. Product Benchmarking
- 10.4.6.4. Strategic Initiatives
- 10.4.7. PierianDx
- 10.4.7.1. Participant’s Overview
- 10.4.7.2. Financial Performance
- 10.4.7.3. Product Benchmarking
- 10.4.7.4. Strategic Initiatives
- 10.4.8. Genomatix GmbH
- 10.4.8.1. Participant’s Overview
- 10.4.8.2. Financial Performance
- 10.4.8.3. Product Benchmarking
- 10.4.8.4. Strategic Initiatives
- 10.4.9. DNASTAR, Inc.
- 10.4.9.1. Participant’s Overview
- 10.4.9.2. Financial Performance
- 10.4.9.3. Product Benchmarking
- 10.4.9.4. Strategic Initiatives
- 10.4.10. Perkin Elmer, Inc.
- 10.4.10.1. Participant’s Overview
- 10.4.10.2. Financial Performance
- 10.4.10.3. Product Benchmarking
- 10.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
